Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
2.7
3.2
Journals
Life
Special Issues
Emerging Anti-cancer Therapeutics and Cancer Drug Resistance
share announcement

Emerging Anti-cancer Therapeutics and Cancer Drug Resistance

A special issue of Life (ISSN 2075-1729). This special issue belongs to the section "Pharmaceutical Science".

Deadline for manuscript submissions: closed (31 March 2022) | Viewed by 9736

Special Issue Editors

Dr. Lingtao Jin

E-Mail Website
Guest Editor
Department of Anatomy and Cell Biology, College of Medicine, University of Florida, Gainesville, FL 32611, USA
Interests: cancer metabolism; therapy resistance; kinase signaling
Dr. Guangrong Zheng

E-Mail Website
Guest Editor
Department of Medicinal Chemistry, College of Pharmacy, University of Florida, Gainesville, FL 32611, USA
Interests: drug discovery and development; targeted protein degradation; organic synthesis; chemical biology

Special Issue Information

Dear Colleagues,

During the past two decades, anti-cancer therapy has evolved from traditional cytotoxic chemotherapy to selective targeted therapy and antibody-based cancer immunotherapy that target not only the cancer cells, but also the cancer microenvironment. Novel anti-cancer therapeutics, such as covalent inhibitors, proteolysis targeting chimeras (PROTACs), antibody-drug conjugates (ADCs) and chimeric antigen receptor (CAR) T-cell therapy, have ushered in a new era of cancer medicine. This Special Issue aims to cover research topics on emerging anti-cancer therapeutics such as innovative targeted therapies, novel immunotherapies and rational combinatorial therapies. The goal is to improve our understanding of the critical role of the tumor heterogeneity, genetic/epigenetic adaptive response, and tumor microenvironment in defining the efficacy of anti-cancer therapeutics as well as mediating drug resistance. It also aims to reveal novel therapeutic targets for cancer treatment and overcoming drug resistance. Basic cancer biologists and physician scientists are welcome to contribute to this Special Issue.

Dr. Lingtao Jin
Dr. Guangrong Zheng
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • proteolysis targeting chimeras (protacs)
  • drug resistance
  • chimeric antigen receptor (car) t-cell therapy
  • immunotherapy
  • targeted therapy

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

15 pages, 873 KiB  
Review
Impact of Diets on Response to Immune Checkpoint Inhibitors (ICIs) Therapy against Tumors
by Xin Zhang, Huiqin Li, Xiupeng Lv, Li Hu, Wen Li, Meiting Zi and Yonghan He
Life 2022, 12(3), 409; https://doi.org/10.3390/life12030409 - 11 Mar 2022
Cited by 10 | Viewed by 2546
Abstract
Immunotherapy has revolutionized the established therapeutics against tumors. As the major immunotherapy approach, immune checkpoint inhibitors (ICIs) achieved remarkable success in the treatment of malignancies. However, the clinical gains are far from universal and durable, because of the primary and secondary resistance of [...] Read more.
Immunotherapy has revolutionized the established therapeutics against tumors. As the major immunotherapy approach, immune checkpoint inhibitors (ICIs) achieved remarkable success in the treatment of malignancies. However, the clinical gains are far from universal and durable, because of the primary and secondary resistance of tumors to the therapy, or side effects induced by ICIs. There is an urgent need to find safe combinatorial strategies that enhance the response of ICIs for tumor treatment. Diets have an excellent safety profile and have been shown to play pleiotropic roles in tumor prevention, growth, invasion, and metastasis. Accumulating evidence suggests that dietary regimens bolster not only the tolerability but also the efficacy of tumor immunotherapy. In this review, we discussed the mechanisms by which tumor cells evade immune surveillance, focusing on describing the intrinsic and extrinsic mechanisms of resistance to ICIs. We also summarized the impacts of different diets and/or nutrients on the response to ICIs therapy. Combinatory treatments of ICIs therapy with optimized diet regimens own great potential to enhance the efficacy and durable response of ICIs against tumors, which should be routinely considered in clinical settings. Full article
(This article belongs to the Special Issue Emerging Anti-cancer Therapeutics and Cancer Drug Resistance)
►▼ Show Figures

Figure 1

19 pages, 3435 KiB  
Review
The Multiple Roles of Glucose-6-Phosphate Dehydrogenase in Tumorigenesis and Cancer Chemoresistance
by Jiaqi Song, Huanran Sun, Shuai Zhang and Changliang Shan
Life 2022, 12(2), 271; https://doi.org/10.3390/life12020271 - 12 Feb 2022
Cited by 31 | Viewed by 6690
Abstract
The pentose phosphate pathway (PPP) is a branch from glycolysis that begins from glucose-6-phosphate (G6P) and ends up with fructose-6-phosphate (F6P) and glyceraldehyde-3-phosphate (GADP). Its primary physiological significance is to provide nicotinamide adenine dinucleotide phosphate (NADPH) and nucleotides for vital activities such as [...] Read more.
The pentose phosphate pathway (PPP) is a branch from glycolysis that begins from glucose-6-phosphate (G6P) and ends up with fructose-6-phosphate (F6P) and glyceraldehyde-3-phosphate (GADP). Its primary physiological significance is to provide nicotinamide adenine dinucleotide phosphate (NADPH) and nucleotides for vital activities such as reactive oxygen species (ROS) defense and DNA synthesis. Glucose-6-phosphate dehydrogenase (G6PD) is a housekeeping protein with 514 amino acids that is also the rate-limiting enzyme of PPP, catalyzing G6P into 6-phosphogluconolactone (6PGL) and producing the first NADPH of this pathway. Increasing evidence indicates that G6PD is upregulated in diverse cancers, and this dysfunction influences DNA synthesis, DNA repair, cell cycle regulation and redox homeostasis, which provides advantageous conditions for cancer cell growth, epithelial-mesenchymal transition (EMT), invasion, metastasis and chemoresistance. Thus, targeting G6PD by inhibitors has been shown as a promising strategy in treating cancer and reversing chemotherapeutic resistance. In this review, we will summarize the existing knowledge concerning G6PD and discuss its role, regulation and inhibitors in cancer development and chemotherapy resistance. Full article
(This article belongs to the Special Issue Emerging Anti-cancer Therapeutics and Cancer Drug Resistance)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop